Transcriptomics

Dataset Information

0

Identification of cathepsin L as an inter-organ target to mitigate cachexia while enhancing tumor suppression by anti-PD-L1 [TA]


ABSTRACT: Immune checkpoint inhibitors (ICIs) can induce immune-related adverse events (irAEs) due to an overly activated immune system, despite their anti-cancer effects. Here, we observe that ICI treatment is associated with body weight loss in cancer patients. Similarly, anti-PD-L1 exacerbates muscle wasting in cancer cachexia (CAC) mice, despite its tumor suppressive effects, suggesting muscle atrophy as a potential irAE. Notably, CD8+ T cells accumulate in the skeletal muscle of CAC mice, which is amplified by anti-PD-L1. These CD8+ T cells directly promote muscle wasting, but their depletion effectively prevents cachectic features in CAC mice. We identify cathepsin L (CTSL) as an inter-organ target capable of suppressing both cancer and muscle wasting, particularly that driven by CD8+ T cells. Indeed, CTSL blockade effectively mitigates muscle wasting and further enhances the anti-tumor activity of anti-PD-L1. Thus, CTSL represents a dual therapeutic target for both cancer and cachexia, offering the potential to prevent muscle-related irAE when combined with ICIs.

ORGANISM(S): Mus musculus

PROVIDER: GSE278396 | GEO | 2024/10/08

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
Items per page:
1 - 1 of 1

Similar Datasets

2024-11-15 | GSE278765 | GEO
2024-10-01 | GSE278013 | GEO
2021-07-14 | GSE173250 | GEO
2023-09-15 | GSE242812 | GEO
2023-02-02 | PXD035347 | Pride
2016-05-01 | GSE80080 | GEO
2016-05-01 | GSE80081 | GEO
2021-04-01 | GSE133979 | GEO
2024-06-13 | PXD037998 | Pride
2024-06-13 | PXD037862 | Pride